← boardnext 2026-10next 2027-01-07next 2027-01-15next 2027-04-30next 2027-07-30next 2028-04-30next 2029-05next 2030-03-30
IDYA
IDEAYA Biosciencesdistress 3/10 · well-funded / low risk$34.52-1%today-15% from 52w high
Lead: Colorectal Cancer · est. market ~$12B (approx, global)
Revenue
pre-revenue
Liquidity
$973M
Runway
11.3 yrs
Shares 1y
+0%
Price & events
-4.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-3.9%
1W
-1.1%
1M
+12.4%
3M
-0.8%
6M
+46.1%
1Y
-19.5%
2Y
+57.4%
5Y
+155.9%
All
Overview
- Market Cap
- $3.03B
- Volume
- 63.09K
- 52 Week Range
- $21.43 – $40.51
- Total Shares
- 87.86M
- Float Shares
- 87.08M
- Short %
- 12.47%
- % Held by Insiders
- 2.22%
- % Held by Institutions
- 101.90%
- RVOL
- 0.05x
- Beta
- -0.09
Pipeline stages · 8 programs
IDE-161, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDE397, Sacituzumab govitecan
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDE196, Binimetinib, Crizotinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Darovasertib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDE034
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDE892, IDE397
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDE849, durvalumab, IDE161
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
IDE574, Fulvestrant injection
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 10 trials · 10 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10 Estimated 50% readout ~2026-10-31 | Phase 1 | IDE-161, Pembrolizumab | Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC | — | active not recruiting |
| 2027-01-07 Estimated 50% readout ~2027-02-06 | Phase 1 | IDE397, Sacituzumab govitecan | Solid Tumor | — | active not recruiting |
| 2027-01-15 Estimated 50% readout ~2027-03-31 | Phase 2/3 | IDE196, Crizotinib, Pembrolizumab | Metastatic Uveal Melanoma | — | active not recruiting |
| 2027-01-29 Estimated 50% readout ~2027-03-15 | Phase 1/2 | IDE196, Binimetinib, Crizotinib | Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors | — | recruiting |
| 2027-04-30 Estimated 50% readout ~2027-06-14 | Phase 2 | Darovasertibfast trackbreakthrough | Uveal Melanoma | — | active not recruiting |
Show all 10 trials · 5 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-07-30 Estimated 50% readout ~2027-08-29 | Phase 1 | IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | — | recruiting |
| 2028-04-30 Estimated 50% readout ~2028-05-30 | Phase 1 | IDE892, IDE397 | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma | — | recruiting |
| 2029-05 Estimated 50% readout ~2029-06-15 | Phase 1/2 | IDE849, durvalumab, IDE161 | Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3 | — | recruiting |
| 2030-03-30 Estimated 50% readout ~2030-04-29 | Phase 1 | IDE574, Fulvestrant injection | ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma | — | recruiting |
| 2030-10 Estimated 50% readout ~2030-12-15 | Phase 3 | Darovasertibfast trackbreakthrough | Uveal Melanoma | — | recruiting |
Catalyst news & presentations · 24
- in 2026Guided 40%conferencedata presentationsecondaryPhase 1/2IDE397 · Provide updated data from Phase 1/2 combination trial with Trodelvy.SEC 8-K
- by the end of 2026Guided 40%trial initiationsecondaryIDE849 · Initiate monotherapy registrational study.SEC 8-K
- in 2026Guided 40%conferencedata presentationsecondarydarovasertib · Additional details from OptimUM-02 at a major medical conference.SEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)darovasertib · NDA submission for darovasertib + crizotinib in 1L HLA-A*02:01-negative mUM.SEC 8-K
- by the end of 2026Guided 40%regulatory submissionFiled (NDA/BLA)CDKN2A targeted therapy · Submit IND for first-in-class program targeting CDKN2A.SEC 8-K
- 2026-08-10earningsEarningsEarnings releaseyahoo
- Q2 '26trial initiationsecondaryPhase 3darovasertib · Initiate Phase 3 trial in collaboration with Servier.SEC 8-K
- first half of 2026conferencedata presentationsecondaryPhase 1/2IDE397 · Next update for IDE397 and Trodelvy combination trial at medical conferenceSEC 8-K
- Q2 '26trial initiationsecondaryIDE161 · Initiate combination studies with IDE849.SEC 8-K
- Q2 '26enrollment completesecondaryPhase 2darovasertib · Complete enrollment of approximately 80 patients in OptimUM-01.SEC 8-K
- 2026-06-03partnershipIDE892 · Clinical collaboration with Roche to evaluate IDE892 in combination with RG6505 in MTAP-deleted RAS-mutant PDAC.SEC 8-K
- 2026-06-01conferencedata presentationsecondaryPhase 2/3darovasertib · Complete data from OptimUM-02 trial presented at ASCO 2026.SEC 8-K
- 2026-04-08partnershipIDE849 · Clinical collaboration agreement with AstraZeneca to evaluate IDE849 in combination with Imfinzi (durvalumab) in extensive-stage SCLC. Company sponsors study, AstraZeneca supplies Imfinzi.SEC 8-K
- 2026-04-01fda agreementdarovasertib · FDA agreed to review NDA under Real-Time Oncology Review program.SEC 8-K
- Q1 '26readoutPhase 2/3darovasertib · Topline PFS results from Phase 2/3 OptimUM-02 trial.SEC 8-K
- Q1 '26trial initiationsecondaryPhase 1IDE574 · Initiate Phase 1 dose escalation.SEC 8-K
- Q1 '26trial initiationsecondaryPhase 1IDE892 · Initiate Phase 1 monotherapy dose escalation.SEC 8-K
- Q1 '26trial initiationsecondaryPhase 1IDE034 · Initiate Phase 1 dose escalation.SEC 8-K
- 2025-12-04withdrawalIDE275|IDE705 · GSK terminated Collaboration, Option and License Agreement for Werner Helicase (IDE275) and Pol Theta (IDE705) programs.SEC 8-K
- Sunday, October 26, 2025conferencedata presentationsecondaryPhase 1/2darovasertib + crizotinib · Presentation of median OS data from Phase 1/2 OptimUM-01 trial at SMR 2025.SEC 8-K
- Q4 2024trial initiationsecondaryPhase 1/2IDE397 · Initiation of IDE397 and Trodelvy Phase 1/2 combination expansion in MTAP-deletion urothelial cancer.SEC 8-K
- Friday, October 25, 2024 at 3:00pm CESTconferencedata presentationsecondaryPhase 1IDE397 · Late-breaking oral presentation of Phase 1 expansion resultsSEC 8-K
- Friday, October 25, 2024, 9:00am - 3:00pm CESTconferencedata presentationsecondaryIDE161 · Poster presentation on PARG inhibitor preclinical dataSEC 8-K
- 2024-09-23fda agreementdarovasertib · FDA provided guidance in a Type C meeting supporting a potential registration-enabling Phase 3 trial in neoadjuvant uveal melanomaSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $52 (+51% upside) · 14 analysts
- 2026-07-07Truist SecuritiesBuy
- 2026-07-07RBC CapitalOutperform
- 2026-06-12WedbushOutperform
- 2026-06-02WedbushOutperform
- 2026-05-07MizuhoOutperform
- 2026-04-14Goldman SachsNeutral
Competitors — Colorectal Cancer
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- BNTXBioNTech SE$23.1B · D1
- SMMTSummit Therapeutics Inc.$11.6B · D3
- VSTMVerastem, Inc.$515M · D5
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRDFCardiff Oncology, Inc.$59M · D3
- CNTXContext Therapeutics Inc.$57M · D2
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-22ETFs Investing in IDEAYA Biosciences, Inc. Stocks - TradingView
- 2026-07-21IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
- 2026-07-19How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing - Stock Traders Daily
- 2026-07-17IDEAYA Biosciences to present new clinical tria... - Pluang
- 2026-07-17IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs - PR Newswire
- 2026-07-17IDEAYA melanoma data and partner Hengrui's lung cancer results head to ESMO - Stock Titan
- 2026-07-09Ideaya Biosciences chief accounting officer sells $382,130 in stock - Investing.com
- 2026-07-09IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.